A meta-analysis found that although SGLT2i was more appropriate for type 2 diabetes patients who were at high risk of stroke compared to dipeptidyl peptidase 4 inhibitor (DPP-4i), the results of this study showed that SGLT2i did not reduce the risk of stroke (12). The gene discussed is DPP4; the disease is Stroke.